(S1 (S (NP (NP (NP (NN Expression)) (CC and) (NP (NN purification))) (PP (IN of) (NP (NP (DT the) (JJ catalytic) (NN domain)) (PP (IN of) (NP (NP (JJ human) (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (NN receptor) (CD 2)) (PP (IN for) (NP (NN inhibitor) (NN screening))))))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Vascular) (JJ endothelial) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ endothelial) (JJ cell-specific) (NN mitogen)) (, ,)) (VP (MD can) (VP (VB act) (PP (IN in) (NP (JJ tumor-induced) (NN angiogenesis))) (PP (IN by) (S (VP (VBG binding) (PP (TO to) (NP (JJ specific) (NNS receptors))) (PP (IN on) (NP (NP (DT the) (NN surface)) (PP (IN of) (NP (JJ endothelial) (NNS cells))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (CD One)) (PP (IN such) (NP (NN receptor)))) (, ,) (NP (NN VEGFR-2/KDR)) (, ,)) (VP (VBZ plays) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (JJ VEGF-induced) (NN angiogenesis))))) (. .)))
(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VP (VBD expressed) (NP (NP (DT the) (JJ catalytic) (NN domain)) (PP (IN of) (NP (NN VEGFR-2)))) (PP (IN as) (NP (NP (DT a) (JJ soluble) (JJ active) (NN kinase)) (VP (VBG using) (NP (NN Bac-to-Bac) (NN expression) (NN system)))))) (, ,) (CC and) (VP (VBD investigated) (NP (NP (NNS correlations)) (PP (IN between) (NP (NP (NN VEGFR-2) (NN activity)) (CC and) (NP (NP (NN enzyme) (NN concentration)) (, ,) (NP (NN ATP) (NN concentration)) (, ,) (NP (NN substrate) (NN concentration)) (CC and) (NP (JJ divalent) (NN cation) (NN type)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD used) (NP (DT these) (NNS data)) (S (VP (TO to) (VP (VB establish) (NP (NP (DT a) (ADJP (ADJP (JJ convenient)) (, ,) (ADJP (JJ effective)) (CC and) (ADJP (JJ non-radioactive))) (NN ELISA) (NN screening) (NN technique)) (PP (IN for) (NP (NP (DT the) (NP (NN identification)) (CC and) (NP (NN evaluation))) (PP (IN of) (NP (NP (JJ potential) (NNS inhibitors)) (PP (IN for) (NP (NN VEGFR-2) (NN kinase))))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VP (VBD screened) (NP (CD 200) (JJ RTK) (JJ target-based) (NNS compounds))) (CC and) (VP (VBD identified) (NP (NP (NP (CD one)) (PRN (-LRB- -LRB-) (NP (CD TKI-31)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (ADVP (RB potently)) (VP (VBD inhibited) (NP (NP (NN VEGFR-2) (NN kinase) (NN activity)) (PRN (-LRB- -LRB-) (NP (CD IC50=0.596) (NN microM)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN of) (NP (NN NIH3T3/KDR) (NNS cells))) (PP (IN with) (NP (NN TKI-31)))) (VP (VBD blocked) (NP (NP (JJ VEGF-induced) (NN phosphorylation)) (PP (IN of) (NP (NN KDR)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NN TKI-31)) (ADVP (RB dose-dependently)) (VP (VBD suppressed) (NP (NN HUVEC) (NN tube) (NN formation)))) (. .)))
(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (ADVP (RB herein)) (VP (VBP report) (NP (NP (DT a) (ADJP (ADJP (JJ novel)) (, ,) (ADJP (JJ efficient))) (NN method)) (PP (IN for) (S (VP (VP (VBG identifying) (NP (NN VEGFR-2) (NN kinase) (NNS inhibitors))) (CC and) (VP (VB introduce) (NP (NP (CD one)) (, ,) (NP (CD TKI-31))))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB prove) (S (VP (TO to) (VP (VB be) (NP (DT a) (JJ useful) (JJ new) (NN angiogenesis) (NN inhibitor))))))))))) (. .)))
